Gujarat Themis Biosyn reported a 9.8% rise in annual income to Rs 168.25 crore for FY26, though profit after tax marginally declined to Rs 46.68 crore due to higher capital expenditure. The company has completed a major capacity expansion in Vapi and announced two international acquisitions, including Sanofi’s brand portfolio and Japan's MicroBiopharm, marking a shift toward global CDMO capabilities.
Gujarat Themis Biosyn FY26: Income Hits Rs 168.25 Crore
Profit After Tax stood at Rs 46.68 crore for the year ended March 31, 2026.
Reader Takeaway: Revenue growth remains steady, though increased capital investment costs have temporarily pressured bottom-line margins during the transition.
What just happened
Gujarat Themis Biosyn Limited (GTBL) released its FY26 Integrated Annual Report, highlighting a year of significant operational scaling. The company reported a total income of Rs 168.25 crore, a 9.8% increase from the previous year’s Rs 153.23 crore. Profit after tax (PAT) saw a slight decline of 4.29% to Rs 46.68 crore, as the firm absorbed costs related to new infrastructure.
Why this matters
This filing marks a pivotal shift for the company as it moves from domestic API manufacturing to a broader international CDMO (Contract Development and Manufacturing Organization) presence. The completion of the Vapi Fermentation Block expansion—more than doubling capacity from 450 KL to 990 KL—is critical for future volume growth.
Strategic Growth and Acquisitions
GTBL announced two major inorganic moves: an Asset Purchase Agreement with Sanofi to acquire 13 brands in the anti-TB and anti-infective segments, and the 100% acquisition of Japan-based MicroBiopharm Japan Co. Ltd. These moves provide immediate access to 55 global markets and advanced technical capabilities in peptides and enzyme engineering.
Risks to watch
Investors should monitor the integration timeline for the newly acquired international portfolios. Furthermore, while the new synthetic and fermentation-based facility is commissioned, its ability to ramp up utilization and contribute positively to margins remains the primary operational challenge for the coming quarters.
What to track next
The focus will remain on regulatory approvals for the acquisitions and the speed at which the expanded Vapi facility reaches optimal capacity utilization to offset recent transition costs.